Related Experiment Video

Updated: Aug 16, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

[The novelty in the treatment of heart failure]

Dagmara Reingardiene1

  • 1Clinic of Intensive Care Medicine, Kaunas University of Medicine, Kaunas, Lithuania.

Medicina (Kaunas, Lithuania)
|August 3, 2005
PubMed

Insights

Levosimendan, a novel inotropic vasodilator, enhances heart contractility without increasing oxygen demand. This well-tolerated drug offers significant benefits for cardiac failure patients, improving hemodynamics and potentially outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure is a prevalent and costly condition with a poor prognosis despite advances in treatment.
  • Levosimendan represents a novel therapeutic approach for managing cardiac failure.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, and clinical effects of levosimendan.
  • To discuss the therapeutic indications, contraindications, and adverse effects of levosimendan.

Main Methods:

  • Review of existing literature on levosimendan.
  • Analysis of hemodynamic studies, clinical trials, and pharmacological data.

Main Results:

  • Levosimendan enhances myocardial contractility via calcium sensitization, without increasing oxygen demand.
  • It reduces systemic and pulmonary vascular resistance, inducing vasodilation.
  • The drug demonstrates anti-ischemic and anti-stunning effects and is well-tolerated.

Conclusions:

  • Levosimendan is a promising agent for cardiac failure treatment due to its unique mechanism and favorable hemodynamic profile.
  • Further research and clinical application are warranted to fully elucidate its impact on morbidity and mortality.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...